Core Viewpoint - BaiO Pharmaceutical-B (02315) experienced a significant increase of nearly 20%, closing at 34.3 HKD, following its inclusion in the Hong Kong Stock Connect list effective December 24, 2025 [1] Company Summary - BaiO Pharmaceutical is recognized as a leading preclinical CRO and life sciences company in China, possessing a globally advanced gene editing technology platform [1] - The company has a rich resource of model mice and is actively developing its antibody development business through the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - There is strong growth potential for its overseas business, indicating a promising outlook for future expansion [1]

国泰海通证券此前指出，百奥赛图是国内领先的临床前CRO及生命技术企业，拥有全球领先的基因编 辑技术平台，模式小鼠资源丰富，通过"千鼠万抗"计划大力发展抗体开发业务，海外业务增长潜力强 劲。 消息面上，上交所、深交所发布公告称，因百奥赛图-B在香港市场价格稳定期结束且相应A股上市满10 个交易日，根据有关规定，港股通标的证券名单发生调整并自2025年12月24日起生效，调入百奥赛图。 百奥赛图-B(02315)早盘大涨近20%，截至发稿，涨19.51%，报34.3港元，成交额2273.51万港元。 ...

Group 1 - The core viewpoint of the article highlights a significant increase in the stock price of Baiaosaitu-B (02315), which surged nearly 20% in early trading, reaching HKD 34.3 with a trading volume of HKD 22.7351 million [1] - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that Baiaosaitu-B will be added to the Hong Kong Stock Connect eligible securities list effective December 24, 2025, following the end of its price stabilization period in the Hong Kong market and after being listed for 10 trading days in A-shares [1] - Guotai Junan Securities previously noted that Baiaosaitu is a leading preclinical CRO and life technology company in China, possessing a globally advanced gene editing technology platform and abundant resources of model mice, significantly developing its antibody development business through the "Thousand Mice and Ten Thousand Antibodies" initiative, with strong growth potential in overseas markets [1]